AG1 is a global health company that produces science-backed supplements .
How do you define prevention at AG1, and what specific health outcomes are you aiming to influence in the coming years?
AG1 is best known for our flagship product—a daily health drink created to support gut health and fill nutrient gaps that stem from modern lifestyles and the decreasing nutrient density of food. Even people trying to eat well struggle with nutrient quality, and the rise of ultra-processed, high-sugar foods only increases that challenge. AG1 includes vitamins and minerals to help cover common nutrient gaps, along with pre and pro biotics to support gut health, an area with a rapidly growing body of research showing meaningful links to overall health and mental wellbeing.
Our philosophy is “foundational health,” meaning the practices and nutritional inputs you must maintain daily. Consistency matters: adherence is essential for nutrition, supplements, and even medicine.
That’s why we focus on clinically-backed ingredients and high-quality formulation, combined with an easy routine people can stick with. The goal is to support better gut health, provide natural energy, and better immune health with research-backed outcomes that reduce negative health events through consistent daily care.
With the wellness space so crowded, how do you ensure scientific rigor and convince consumers—especially younger, more skeptical ones—that AG1’s benefits are truly backed by science?
You cannot convince consumers unless the science and standards behind your product are real. AG1 has long maintained rigorous third-party certifications, including being NSF Certified for Sport. These certifications confirm that what we claim on the label is actually in the produ ct, and we publish our Certificate of Analysis to show both what is included and what is excluded—pesticides, contaminants, and other agents. Third-party verification is essential in this industry.
But content is only part of the proof. For every ingredient used to support a specific benefit, we rely on published, peer-reviewed university research—not in-house studies—at the right dose and quality. We then go further by running multiple double-blind, randomized, placebo-controlled human trials on the finished formula, because ingredients can behave differently in combination. We tested AG1 across four populations—athletes, non-athletes, varied diets, varied gut profiles—to ensure consistency. That level of research is rare in supplements, but essential for credibility.
Could you speak about your partnership with UC Davis’ Innovation Institute for Food and Health, especially in the context of growing focus on metabolic health and the rise of GLP-1 medications?
It’s an important moment given the rapid adoption of GLP-1 drugs. Without speaking to the medical side, the behavioural reality is clear: people taking these medications are eating less. When you reduce food intake—particularly if your diet is already low in nutrients or gut health is already challenged—those issues do not improve. Eating less means accessing fewer nutrients and reducing plant diversity, which directly reduces microbiome diversity and affects mental health, vitality, digestion, and immunity. This has created a growing need for nutrient-dense, research-backed supplementation like AG1.
But we can’t simply rely on anecdotes; we need data. That’s why we partnered with UC Davis, an institution already leading work at the intersection of metabolic health, food, and the microbiome. We are funding multi-year research to better understand how nutrition interacts with GLP-1 use. The findings will support the wider scientific community, and we will apply them to validate how AG1 addresses nutrient gaps and microbiome challenges intensified by these drugs. It’s the responsible way to approach a changing landscape.
Is there anything consumers should avoid when combining nutrients—ingredients that don’t work well together or may reduce efficacy?
We’ve learned a lot through our own product development. Years ago, AG1 included flaxseed, which is healthy, but certain fibres can block the absorption of key vitamins and minerals. Because we prioritise bioavailability, we removed it so the multivitamin components would absorb properly. Another example is Vitamin D3 and K2. D3 is fat-soluble, so it cannot be effectively absorbed when consumed in water. Putting it into a powder would be easier, but it simply would not work.
For this reason, we offer D3 + K2 as an oil-based dropper, allowing proper absorption and seasonal adjustment of intake. K2 also carries considerations for people with certain heart conditions, another reason not to include it broadly in a powder formula. These examples show how certain combinations enhance effectiveness while others diminish it. Our goal is to do the research, secure certifications, and make foundational supplementation both simple and effective.
As wellness trends shift—with a new administration focused on prevention, and changing consumer behaviour—where do you see AG1 in the next two to three years?
Large consumer brands are beginning to elevate their portfolios with genuinely health-forward food and nutrition products, and capital markets are rewarding wellness companies that scale efficiently. Consumers will not unlearn what they’ve heard about the harms of processed foods, the importance of nutrient density, or the role of gut health. We’re at a tipping point where companies offering high-quality, research-driven products can finally scale in ways that were previously difficult.
AG1 is well positioned because we’ve spent years building a foundation of quality systems, certifications, and research capability. We expect to continue raising the bar and expanding into precision nutrition—not personalised products, but foundational nutrition tailored to life stages and specific needs. That may include versions of AG1 for people with exceptional gut health needs or for different demographic groups. The foundation is set; now we focus on meeting a growing demand for proactive, research-backed daily health solutions.
